Cargando…
Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies
Advances in the treatment of rheumatoid arthritis (RA) are attributed to several aspects such as new classification criteria enabling early diagnosis and intensive treatment with the application of treat-to-target principles as well as better understanding of the pathogenesis of RA contributing to t...
Autor principal: | Senolt, Ladislav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719675/ https://www.ncbi.nlm.nih.gov/pubmed/31508202 http://dx.doi.org/10.12688/f1000research.18688.1 |
Ejemplares similares
-
Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis
por: Lim, Sung Ho, et al.
Publicado: (2022) -
Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis?
por: Šenolt, Ladislav, et al.
Publicado: (2014) -
Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments
por: Chi, Xiao-Kai, et al.
Publicado: (2023) -
Targeted therapies in rheumatoid arthritis: Focus on rituximab
por: Teng, YKO, et al.
Publicado: (2007) -
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
por: Isaacs, JD, et al.
Publicado: (2005)